Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
Status:
Not yet recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial finds the best dose and side effects of venetoclax in combination with
cladribine, cytarabine, granulocyte colony-stimulating factor, and mitoxantrone (CLAG-M) in
treating patients with acute myeloid leukemia and high-grade myeloid neoplasms. Venetoclax
may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell
survival. Chemotherapy drugs, such as cladribine, cytarabine, and mitoxantrone, work in
different ways to stop the growth of cancer cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. Giving venetoclax with CLAG-M may
kill more cancer cells.